Phase I study of recombinant human tumor
β
T. Moritz; N. Niederle; J. Baumann; D. May; E. Kurschel; R. Osieka; J. Kempeni;
π
Article
π
1989
π
Springer-Verlag
π
English
β 643 KB
A phase I study withrecombinant human tumor necrosis factor a (rhuTNF-a; Knoll AG, Ludwigshafen, FRG) in patients with advanced malignant disease was undertaken to evaluate drug toxicity (organ specifity, time course, predictability, reversibility, maximal tolerated dose), effectiveness, antigenicit